Transaction details
Daphne Karydas, a director at Mineralys Therapeutics Inc (NASDAQ: MLYS), reported a sale of 3,000 common shares on March 31, 2026, at a per-share price of $25, representing total proceeds of $75,000. On the same date, Karydas exercised stock options to acquire an additional 3,000 shares at an exercise price of $12.02, for a total exercise cost of $36,060.
Ownership and trading plan
Following those transactions, Karydas directly holds 6,200 shares of Mineralys Therapeutics. The sale and option exercise were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that the director adopted on December 30, 2025.
Share performance and valuation cues
MLYS has demonstrated notable price momentum, trading most recently at $26.97 and delivering a 92.6% total return over the past 12 months. According to InvestingPro analysis quoted in company-related reporting, the stock appears overvalued relative to its Fair Value, although published analyst targets span a wide range from $30 to $56. The InvestingPro platform is noted to offer deeper coverage through Pro Research Reports for MLYS and more than 1,400 U.S. equities.
Financial results and market reaction
Mineralys reported fourth-quarter 2025 results that beat consensus on the earnings per share line, posting EPS of -0.4 compared with a forecast of -0.94. Despite the stronger-than-expected EPS, market participants registered concerns about rising general and administrative expenses.
Analyst actions and commercial-readiness signals
Brokerage views on Mineralys diverge. BofA Securities raised its price target to $51 and maintained a Buy rating, citing progress in the clinical development of the company’s lead asset, lorundrostat. Stifel likewise reiterated a Buy rating and set a $52 price target, highlighting preparations for a commercial launch following the FDA’s acceptance of Mineralys’ New Drug Application. By contrast, Jefferies trimmed its price target to $30 while retaining a Hold rating, pointing to uncertainties around the strategy to realize lorundrostat’s value.
Corporate update
In a separate management move, Mineralys appointed Jeffrey Munsie as Chief Legal Officer. The company noted that Munsie brings nearly 25 years of legal experience in the biopharmaceutical industry.
Context
Taken together, the insider transaction, recent quarterly results, analyst revisions and the new legal hire reflect a company engaged in operational and strategic activity as it advances drug development and works toward commercialization milestones for lorundrostat.